CMPX

Compass Therapeutics' stock has been volatile over the past six months. On April 27, 2026, the stock dropped 64-80% after mixed Phase 2/3 trial results for tovecimig, which met progression-free survival but not overall survival. On August 6, 2026, shares gained 5.3% following Q2 financial results and a corporate update. On September 22, 2026, shares plummeted over 25% after the FDA recommended an additional survival benefit trial for tovecimig, delaying its path to market. On October 2, 2026, the company's accounting chief purchased 20,000 shares. Overall, the stock has decreased by 74.8% over the past year.